| Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics U Arshad, H Pertinez, H Box, L Tatham, RKR Rajoli, P Curley, M Neary, ... Clinical Pharmacology & Therapeutics 108 (4), 775-790, 2020 | 154 | 2020 |
| Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a … MR Smit, EO Ochomo, G Aljayyoussi, TK Kwambai, BO Abong'o, T Chen, ... The Lancet Infectious Diseases 18 (6), 615-626, 2018 | 132 | 2018 |
| Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and … G Aljayyoussi, HE Tyrer, L Ford, H Sjoberg, N Pionnier, D Waterhouse, ... Scientific reports 7 (1), 210, 2017 | 75 | 2017 |
| Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and … G Aljayyoussi, HE Tyrer, L Ford, H Sjoberg, N Pionnier, D Waterhouse, ... Scientific reports 7 (1), 210, 2017 | 75 | 2017 |
| Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis MJ Taylor, TW von Geldern, L Ford, MP Hübner, K Marsh, KL Johnston, ... Science translational medicine 11 (483), eaau2086, 2019 | 73 | 2019 |
| Saliva alternative to upper respiratory swabs for SARS-CoV-2 diagnosis RL Byrne, GA Kay, K Kontogianni, G Aljayyoussi, L Brown, AM Collins, ... Emerging infectious diseases 26 (11), 2769, 2020 | 71 | 2020 |
| AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis WD Hong, F Benayoud, GL Nixon, L Ford, KL Johnston, RH Clare, ... Proceedings of the National Academy of Sciences 116 (4), 1414-1419, 2019 | 68 | 2019 |
| A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance PM O’Neill, RK Amewu, SA Charman, S Sabbani, NF Gnädig, J Straimer, ... Nature Communications 8 (1), 15159, 2017 | 67 | 2017 |
| Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study HC Slater, BD Foy, K Kobylinski, C Chaccour, OJ Watson, J Hellewell, ... The Lancet Infectious Diseases 20 (4), 498-508, 2020 | 65 | 2020 |
| Spatial expression and functionality of drug transporters in the intact lung: objectives for further research M Gumbleton, G Al-Jayyoussi, A Crandon-Lewis, D Francombe, ... Advanced drug delivery reviews 63 (1-2), 110-118, 2011 | 65 | 2011 |
| Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis RKR Rajoli, H Pertinez, U Arshad, H Box, L Tatham, P Curley, M Neary, ... British Journal of Clinical Pharmacology 87 (4), 2078-2088, 2021 | 63 | 2021 |
| Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis JD Turner, R Sharma, G Al Jayoussi, HE Tyrer, J Gamble, L Hayward, ... Proceedings of the National Academy of Sciences 114 (45), E9712-E9721, 2017 | 54 | 2017 |
| Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis WD Hong, PD Gibbons, SC Leung, R Amewu, PA Stocks, A Stachulski, ... Journal of medicinal chemistry 60 (9), 3703-3726, 2017 | 48 | 2017 |
| Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration G Aljayyoussi, VA Jenkins, R Sharma, A Ardrey, S Donnellan, SA Ward, ... Scientific reports 7 (1), 502, 2017 | 43 | 2017 |
| Population pharmacokinetics of liposomal amphotericin B in immunocompromised children JM Lestner, AH Groll, G Aljayyoussi, NL Seibel, A Shad, C Gonzalez, ... Antimicrobial agents and chemotherapy 60 (12), 7340-7346, 2016 | 43 | 2016 |
| Therapeutic potential of nitazoxanide: an appropriate choice for repurposing versus SARS-CoV-2? AV Stachulski, J Taujanskas, SL Pate, RKR Rajoli, G Aljayyoussi, ... ACS infectious diseases 7 (6), 1317-1331, 2020 | 41 | 2020 |
| Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic … R Sharma, GA Jayoussi, HE Tyrer, J Gamble, L Hayward, AF Guimaraes, ... Scientific reports 6 (1), 23458, 2016 | 41 | 2016 |
| Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease L Campbell, G Al-Jayyoussi, R Gutteridge, N Gumbleton, R Griffiths, ... Journal of translational medicine 11, 1-14, 2013 | 40 | 2013 |
| Pharmaceutical nanoparticles and the mucin biopolymer barrier G Aljayyoussi, M Abdulkarim, P Griffiths, M Gumbleton BioImpacts: BI 2 (4), 173, 2012 | 37 | 2012 |
| Pharmacokinetics‐pharmacodynamics of high‐dose ivermectin with dihydroartemisinin‐piperaquine on mosquitocidal activity and QT‐prolongation (IVERMAL) MR Smit, EO Ochomo, D Waterhouse, TK Kwambai, BO Abong'o, ... Clinical Pharmacology & Therapeutics 105 (2), 388-401, 2019 | 36 | 2019 |
